新辅助化疗治疗晚期子宫内膜癌的临床疗效及并发症分析  

Clinical efficacy and complications of neoadjuvant chemotherapy for advanced endometrial carcinoma

作　　者：马焱[1] 董志红[1] 刘爽[1] 李莉[1] 

机构地区：[1]新疆医科大学附属肿瘤医院妇外一科,乌鲁木齐830011

出　　处：《中国妇产科临床杂志》2017年第5期404-406,共3页Chinese Journal of Clinical Obstetrics and Gynecology

摘　　要：目的分析新辅助化疗治疗晚期子宫内膜癌疗效。方法收集2012年2月至2013年6月新疆医科大学附属肿瘤医院收治的子宫内膜癌患者74例,随机分为对照组、观察组各37例;对照组采用常规手术治疗,术后辅助放化疗、激素治疗,观察组联合术前辅助化疗。结果新辅助化疗完全缓解2.7%、部分缓解54.1%、稳定40.5%、进展2.7%,缓解56.8%,控制97.3%;观察组术中出血量、手术时间低于对照组,观察组无瘤生存时间(24.4±5.6)个月,高于对照组(20.3±5.1)个月,对照组总有效率54.04%低于观察组75.68%,差异有统计学意义(P<0.05);观察组、对照组生活质量术后明显下降,差异有统计学意义,(P<0.05);两组之间治疗前、化疗后、手术后生活质量比较差异无统计学意义(P>0.05)。结论新辅助化疗治疗晚期子宫内膜癌可增进近期疗效,但可能导致肿瘤进展。Objective To analyze the neoadjuvant chemotherapy in the treatment of advanced endometrial cancer. Methods 74 cases of endometrial carcinoma from February 2012 to June 2013 were selected, and randomly divided into control group and observation group, with 37 cases in each one. The control group were given routine surgical treatment, postoperative adjuvant chemotherapy, hormone therapy, observation group added with preoperative adjuvant chemotherapy. Results The complete remission rate of neoadjuvant chemotherapy was 2.7%, partial remission rate was 54.1%, the stable rate was 40.5%, the progression rate was 2.7% and the remission rate was 56.8%, control rate was 97.3%. Amount of bleeding and operation time of the observation group were lower than the control group, the tumor free survival time of observation group was （24.4± 5.6） months, longer than （20.3± 5.1） months of the control group , the total efficiency of the control group was 54.04%, lower than 75.68% of the observation group （P〈0.05）. The life quality in both group decreased obviously after operation, and the difference were both statistically significant （P〈0.05）. There was no significant difference in the life quality between the two groups before and after chemotherapy and after operation. （P〉0.05）. Conclusion The neoadjuvant chemotherapy in the treatment of advanced endometrial carcinoma can improve the short-term efficacy, but may lead to tumor progression.

关 键 词：新辅助化疗 晚期子宫内膜癌 临床疗效 并发症 

分 类 号：R737.33[医药卫生—肿瘤]